Alerta

B-ISOXAZOLE DERIVATIVES, DIAGNOSTIC COMPOSITIONS; AND METHODS RELATED THERETO

Resumen de: AU2024401251A1

The present application relates to novel b-isox analogs for use in detecting misfolded proteins associated with neurodegenerative diseases, such as ALS, PD, AD, FTLD, and LATE. The present inventors identified and modified a specific site on the b-isox molecule, which significantly enhances detection capabilities. This modification also allows for the selection of analogs that either exhibit low background interference or alter cellular targets, based on the alteration of a functional group at critical site.

METHODS FOR CLASSIFYING, DETECTING AND TREATING BIOLOGICAL DISEASES

Resumen de: AU2024399715A1

The current disclosure provides for methods and compositions for classifying subjects having different biological states. The disclosure describes a method comprising: filtering sequence data obtained from a sample from a subject based on long non-coding RNA (lncRNA) and/or pseudogene RNA (pgRNA), and/or the reference genome; determining a biological state classification of the subject by providing the filtered sequence data to one or more machine learning classifiers as input, wherein the one or more machine learning classifiers is trained to output biological state classifications based on filtered sequence data of a training data set.

PEPTIDE BIOMARKER

Resumen de: US20260210980A1

The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.

Organic Electrolyte-Gated Field Effect Transistor Biosensor

Resumen de: US20260210903A1

0000 An organic electrolyte-gated field effect transistor biosensor contains a microfluidic channel structure formed from a dielectric thermoplastic material. A biorecognition entity immobilized within the microfluidic channel allows the biosensor to detect the presence or concentration of an analyte in an electrolyte fluid placed within the channel. The dielectric material separates the microfluidic channel from the gate electrode and from the semiconductor material connecting the drain and source electrodes, and protects the gate electrode and the semiconductor material from direct contact with the electrolyte fluid in the microfluidic channel, to provide the biosensor with a high capacitance. Methods of fabricating the biosensor by monolithic 3D printing are also provided.

BRAWNIN AGONISTS FOR USE IN THE TREATMENT OF AXONAL METABOLIC DISORDERS

Resumen de: US20260210943A1

Using primary mouse neuronal cultures and mouse models, the present inventors have highlighted the role of a new effector, BRAWNIN, in neuronal metabolic balance and cortical axon branching. The present inventors have shown that BRAWNIN expression is necessary and sufficient for cortical axon branching. The present inventors have particularly demonstrated that BRAWNIN expression allows completely restoring impaired axon branching phenotypes in an impaired axon development mouse model. The present invention therefore pertains to a BRAWNIN agonist for use in the treatment of axonal metabolic disorders. The present invention further pertains to screening methods for the identification of novel therapeutic compounds based on BRAWNIN expression in a cellular model.

Single-domain antibodies directed against gasdermin D and their use

Resumen de: US20260209323A1

The present invention is concerned with single-domain antibodies directed against gasdermin D (GSDMD). The single-domain antibodies can be used in medical applications, preferably for preventing and/or treating an inflammatory disease or condition in a subject, and/or for determining the presence or absence of GSDMD oligomers in a sample obtained from a subject.

METHODS OF TREATING A COGNITIVE IMPAIRMENT

Resumen de: AU2025226972A1

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.

METHOD TO DETECT AND TREAT PERIPHERAL NEUROPATHY

Resumen de: US20260210976A1

Disclosed herein is a kit to detect and determine post-synaptic density protein-95 (PSD-95) levels in subjects with peripheral neuropathy. Also disclosed herein, is a method of treating or preventing neuropathy in a subject. The method comprises detecting PSD-95 levels in a sample from the subject, using the kit disclosed herein and when the PSD-95 level differs from a control, the subject is treated for neuropathy.

IMPROVED PEPTIDE INHIBITORS OF P53 BINDING PROTEIN 53BP1

Resumen de: US20260207777A1

0000 Compositions and methods are provided for enhancing homology-directed repair in gene-editing applications using improved inhibitors of 53BP1.

METHODS OF PROGNOSIS FOR HEMORRHAGIC TRANSFORMATION FOLLOWING ENDOVASCULAR TREATMENT

Resumen de: US20260210974A1

Methods are provided for classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome following endovascular treatment (EVT) in an individual suffering from an acute ischemic stroke with respect to development of hemorrhagic transformation (HT). The data and integrated model provided herein demonstrates a pre-operative assessment of single-cell biomarkers for accurate prediction of HT following EVT in individuals suffering from acute ischemic strokes. The integrated model incorporates “immune features” such as activation of signaling proteins and/or the frequency of specific cell subset(s). The analysis and prediction of HT is used to guide therapeutic approaches to EVT and the post-treatment care. Specifically, the level of certain features (e.g. elevated prpS6 in memory Th1 CD4+T cells, elevated pCREB in naïve Th1 CD4+T cells and increased frequency of non-classical monocytes) demonstrate an increased likelihood of HT occurring following EVT.

MULTIPARAMETRIC INTEGRATED MOLECULAR DETECTION OF VIRAL ANTIGENS AND VIRAL NUCLEIC ACIDS

Resumen de: US20260210962A1

0000 Disclosed herein are methods for detecting and treating viral infections. Disclosed is a method of detecting a virus, comprising obtaining a biological sample; capturing a plurality of membranous particles from the biological sample; measuring antigens and nucleic acid levels in the membranous particles or single virions from the biological sample; and measuring an amount of a viral RNA; wherein a virus is detected when the viral protein level or the amount of viral RNA is increased in comparison to a control sample.

HIGH DENSITY MICROARRAYS AND USES THEREOF

Resumen de: US20260210959A1

The present disclosure relates to high density microarrays, methods of manufacturing the arrays, and uses thereof. In particular, the present disclosure provides high density microarrays of biological molecules that allow for specific and sensitive biological assays.

SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE

Resumen de: US20260210977A1

The invention relates to 5 serum peptide patterns for diagnostics of acute ischemic stroke (AIS) in humans and differential diagnosis from the intracranial hemorrhagic stroke that are defined using a list of the 100 quantitative peptides that in sera of patients with AIS are increased 2 folds or more as compared with individuals without stroke and patients with intracranial hemorrhagic stroke and a list of 54 qualitative peptides detectable in sera of the patients with AIS but not detectable in the sera of individuals without stroke and in sera of patients with intracranial hemorrhagic stroke.

DIAGNOSIS AND TREATMENT OF LONG-COVID

Resumen de: US20260210975A1

0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.

METHODS FOR PREDICTIVE MODELING OF ALZHEIMER'S DISEASE AND PROGRESSION

Resumen de: WO2026156364A1

Provided herein is the identification of target proteins for determination of clinical aspects of Alzheimer's disease in a subject. Further provided are methods for diagnosing Alzheimer's disease, determining the progression or rate of memory decline of Alzheimer's disease, and predicting amyloid-tau status, brain amyloidosis status, and plasma p-tau217 status of a subject, using predictor value comparison to thresholds. Also provided are methods of selecting a subject for inclusion in a clinical trial, methods for treating the subject in need thereof, and kits providing the same.

マススペクトロメトリーによるアミロイドベータの検出

Resumen de: CN108291916A

Provided are methods for the detection or quantization of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Abeta42) to amyloid beta 40 (Abeta40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

Method for classification of complex samples by low-resolution separation techniques

Resumen de: SE2530023A1

0001 Abstract This invention relates to analytical chemistry, and can be used in life sciences, including medicine. It provides a method for classifying a given complex sample into prespecified subgroups. The sample is composed of a mixture of compounds and it is analyzed by a technique with resolving power insufficient for separating individual compounds. As an example, the method can be used for assessing by blood sample analysis the risk of its donor for developing or fast progression of a neurological disease caused by protein aggregation. The invention is also suitable for assessing the quality of human blood plasma stored in blood storage facilities and suitability of that plasma for transfusion or further storage.

グルコシルセラミダーゼベータ１欠損に関連する障害の治療のための組成物及び方法

Resumen de: WO2024229161A1

The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).

単離された内皮前駆細胞を含む組成物及びそれらの使用

Resumen de: WO2025004009A1

The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+/- PDGFRA+/- EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.

CO-CULTURES OF ORGANOIDS, STROMAL CELLS AND IMMUNE CELLS

Resumen de: EP4779306A1

0001 The present invention relates to organoid co-cultures and their use in the investigation of diseases. The co-culture comprises at least one organoid, at least one stromal cell, and at least one immune cell. The presence or absence of the at least one change in the co-culture is determined e.g. in response to a proinflammatory stimulus.

一种靶向Gal3的抗体及其应用

Resumen de: CN122427282A

本发明公开了一种靶向Gal3的抗体及其应用。所述抗体包括轻链可变区和重链可变区，其中，所述重链可变区包含氨基酸序列分别如SEQ ID NO:6、SEQ ID NO:7和SEQ ID NO:8所示的HCDR1、HCDR2和HCDR3；和/或，所述轻链可变区包含氨基酸序列分别如SEQ ID NO:10、SEQ ID NO:11和SEQ ID NO:12所示的LCDR1、LCDR2和LCDR3。本发明提供的抗体能对抑制TGF‑β/Gal3诱导的小鼠胚胎成纤维细胞NIH3T3纤维化过程，可显著改善博莱霉素诱导的小鼠呼吸功能损伤，可有效恢复阿霉素、心肌梗死和糖尿病心肌病诱导的心衰小鼠的心脏收缩功能、逆转心室异常重构进程和逆转心脏病理组织改变。

肺炎球菌溶血素纳米孔

Resumen de: WO2025120010A1

The invention relates to a nanopore-based sensing device. In one aspect of the invention, a nanopore-based sensing device comprises at least one membrane, wherein the membrane is arranged in a way that it separates two compartments within the device, both of which are accessible by an electrode, the membrane comprising at least one nanopore comprising pneumolysin (PLY) monomers.

诊断剂

Resumen de: WO2025120152A1

The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET) -associated pathologies.

用于利用质膜锚定蛋白酶的系统和方法

Resumen de: WO2025059015A1

Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.

美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用

Nº publicación: CN122410031A 17/07/2026

Solicitante:

中国医学科学院肿瘤医院深圳医院

Resumen de: CN122410031A

本发明提供了美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用，属于生物医药技术领域。本发明发现GluN2A蛋白是小细胞肺癌不良预后及靶向干预的重要分子标志物。另外，本发明发现美金刚、其衍生物或药用盐能够以剂量依赖的方式显著抑制小细胞肺癌细胞的活力、克隆形成能力、DNA复制活性及迁移能力，并有效破坏3D肿瘤球体的形成、诱导肿瘤细胞死亡，显著减小了小细胞肺癌异种移植瘤的体积和重量。本发明提供的伴随诊断与靶向用药策略，克服了传统非选择性用药的盲目性，为现有小细胞肺癌的治疗提供了新的药物解决方案。